Company profile for Oncopeptides

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Oncopeptides is a pharmaceutical company focused on the development of therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen in multiple myeloma. Melflufen is a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells. Melflufen is currently being tested in four clinical studies including the pivotal phase 2 HO...
Oncopeptides is a pharmaceutical company focused on the development of therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen in multiple myeloma. Melflufen is a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells. Melflufen is currently being tested in four clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study, the phase 1/2 combination study ANCHOR and the phase 2 Study BRIDGE.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Sweden
Address
Address
Luntmakargatan 46, vån 7 SE-111 37 Stockholm
Telephone
Telephone
+46 8 615 20 40
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2025-11-11/annals-of-hematology-expert-consensus-supports-use-of-pepaxti-in-myeloma

PHARMIWEB
11 Nov 2025

https://www.pharmiweb.com/press-release/2025-11-04/research-by-top-universities-together-with-oncopeptides-on-nk-cell-engagers-to-be-presented-at-ash

PHARMIWEB
04 Nov 2025

https://www.pharmiweb.com/press-release/2025-10-23/oncopeptides-to-host-capital-markets-update-featuring-leading-global-experts-in-multiple-myeloma

PHARMIWEB
23 Oct 2025

https://www.pharmiweb.com/press-release/2025-02-27/issue-and-re-purchase-of-class-c-shares-for-shareholder-program

PHARMAWEB
27 Feb 2025

https://www.pharmiweb.com/press-release/2025-02-25/strong-real-world-efficacy-and-safety-data-with-pepaxti-published-in-the-european-journal-of-haematology

PHARMAWEB
25 Feb 2025

https://www.pharmiweb.com/press-release/2025-01-28/oncopeptides-pepaxti-formally-approved-for-full-reimbursement-in-italy

PHARMAWEB
28 Jan 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty